Cancer drug developer RenovoRx's Q3 net loss widens

RenovoRx

13/11/2025 21:38

Overview

RenovoRx Q3 revenue at $266,000, reflecting early-stage commercialization progress

Net loss for Q3 2025 was $2.9 mln, compared to $2.5 mln in Q3 2024

Company expects revenue growth in 2026 to offset cash burn

Outlook

RenovoRx expects revenue growth in 2026 to offset cash burn

RenovoRx plans strategic expansion with increased physician advocacy

Result Drivers

COMMERCIAL EXPANSION - RenovoRx expanded from 5 to 14 cancer centers approved to purchase RenovoCath, reflecting growing market adoption

SALES TEAM GROWTH - Co hired new sales leadership, including Philip Stocton as Senior Director of Sales, to support commercialization

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Net Income
-$2.91 mln
Q3 Basic EPS
-$0.08
Q3 Operating Expenses
$3.41 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

Wall Street's median 12-month price target for RenovoRx Inc is $3.75, about 73.3% above its November 12 closing price of $1.00

Press Release: ID:nGNX8XzfdS

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)